UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
‘Diabetes treatment Forxiga born as new heart drug in DAPA-HF study’
“The DAPA-HF trial results announced in the recent European Society of Card...
by Kim Yun-mi
|
2019-09-23 11:45
라인
Takeda Korea labor union to ask Japanese headquarters about restructuring
Takeda Pharmaceutical Korea’s trade union, in dispute with management durin...
by Kim Yun-mi
|
2019-09-19 14:11
라인
Korea unlikely to include hepatitis C test in state-backed health checkup
The government is unlikely to designate a hepatitis C antibody test as a he...
by Kim Yun-mi
|
2019-09-18 15:50
라인
Will Tagrisso study results affect use of EGFR TKIs in lung cancer?
AstraZeneca’s imminent announcement of overall survival (OS) data of Tagris...
by Kim Yun-mi
|
2019-09-18 11:36
라인
‘Lundbeck to work with parliament to prevent suicide in Korea’
Lundbeck, which sells anti-depressants Lexapro and Brintellix, dementia tre...
by Kim Yun-mi
|
2019-09-17 15:19
라인
Lenvima to get benefit as 1st-line treatment of hepatocellular carcinoma
Lenvima (ingredient: lenvatinib), a new liver cancer drug that arrived in a...
by Kim Yun-mi
|
2019-09-16 16:20
라인
FDA warns against pneumonitis with CDK 4/6 inhibitor drugs for breast cancer
The U.S. Food and Drug Administration added a warning that the entire class...
by Kim Yun-mi
|
2019-09-16 11:39
라인
AstraZeneca to challenge Roche in small-cell lung cancer treatment market
AstraZeneca’s Imfinzi (ingredient: durvalumab) has sharpened up its weapon ...
by Kim Yun-mi
|
2019-09-11 14:18
라인
PARP inhibitors to show intense rivalry at ESMO 2019
The highlight of the upcoming ESMO 2019, a cancer meeting in Europe, will b...
by Kim Yun-mi
|
2019-09-09 11:56
라인
‘No antibiotic works for patients with multidrug-resistant infections’
The number of patients with multidrug resistant bacteria such as Carbapenem...
by Kim Yun-mi
|
2019-09-06 15:11
라인
‘Government is doing best to relieve pain of atopic dermatitis patients’
The Health Insurance Review and Assessment Service (HIRA) held a closed-doo...
by Kim Yun-mi
|
2019-09-05 11:48
라인
Takeda Korea vows to release 16 new drugs by 2023
Takeda Pharmaceutical Korea on Tuesday held the first news conference after...
by Kim Yun-mi
|
2019-09-03 15:40
라인
Real-world data of Saxenda disclosed for 1st time in Asia
Korean researchers have disclosed Asia’s first real-world data of Saxenda, ...
by Kim Yun-mi
|
2019-09-02 14:39
라인
Antidiabetic Forxiga proves efficacy in heart failure
AstraZeneca said it has confirmed that its diabetes drug Forxiga (ingredien...
by Kim Yun-mi
|
2019-09-02 11:35
라인
Atopic dermatitis patients fall in despair as Dupixent may not get coverage soon
Sanofi’s new biologic agent Dupixent (ingredient: dupilumab) for severe ato...
by Kim Yun-mi
|
2019-08-30 16:26
라인
CAR-T therapy Kymriah, pie in the sky for Korean patients
Kymriah, Novartis’ new CAR-T (chimeric antigen receptor T-cell) treatment, ...
by Kim Yun-mi
|
2019-08-29 14:35
라인
‘GI Innovation will be small but strong leader of bioindustry’
“GI Innovation, armed with both basic science and development strategy, wil...
by Kim Yun-mi
|
2019-08-27 15:57
라인
‘Drug firm’s pick of doctor to attend conference overseas illegal’
Pharmaceutical companies’ support for physicians to attend academic confere...
by Kim Yun-mi
|
2019-08-22 15:45
라인
Rivalry among PARP inhibitors intense in ovarian cancer treatment
Pharmaceutical firms’ war using PARP inhibitors, a group of pharmacological...
by Kim Yun-mi
|
2019-08-19 14:00
라인
Diabetes drug Jardiance pressures heart failure treatment Entresto
Novartis’ new heart failure treatment Entresto (ingredient: sacubitril/vals...
by Kim Yun-mi
|
2019-08-09 15:44
-
1
2
3
4
5
6
7
8
9
10
다음
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top